Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215-225].

Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Williams A, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, McGrath M.

Nucl Med Biol. 2016 Dec;43(12):837. doi: 10.1016/j.nucmedbio.2016.10.001. No abstract available.

PMID:
27866590
2.

The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.

Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Williams A, McGrath M.

Nucl Med Biol. 2016 Mar;43(3):215-25. doi: 10.1016/j.nucmedbio.2015.11.007. Epub 2015 Dec 3. Review.

3.

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.

Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA.

Blood. 2013 Sep 19;122(12):2104-13. doi: 10.1182/blood-2013-02-485441. Epub 2013 Aug 2.

4.

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Mac-Gregor Cortelli B, Blumel S, Evens AM, Zelenetz AD, Wright J, Cooper B, Winter J, Vose J.

Clin Cancer Res. 2010 Jan 15;16(2):719-26. doi: 10.1158/1078-0432.CCR-08-2647. Epub 2010 Jan 12.

5.

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD.

J Clin Oncol. 2009 Sep 10;27(26):4357-64. doi: 10.1200/JCO.2008.20.8470. Epub 2009 Aug 3.

6.

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.

Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, Zhang Z, Dumitrescu O, Sarasohn D, Lin D, Pappanicholaou J, Cortelli BM, Neylon E, Hamelers R, Wright J, O'Connor OA.

Br J Haematol. 2009 Sep;146(6):652-5. doi: 10.1111/j.1365-2141.2009.07775.x. Epub 2009 Jul 16.

7.

A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.

Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, Sirotnak F, Fleisher M, Saunders ME, O'Connor OA.

Clin Pharmacol Ther. 2009 Aug;86(2):190-6. doi: 10.1038/clpt.2009.80. Epub 2009 May 27.

PMID:
19474785
8.

Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia.

Gumbs AA, Zain J, Neylon E, MacGregor-Cortelli B, Patterson M, O'Connor OA.

Ann Surg Oncol. 2009 Jul;16(7):2014-7. doi: 10.1245/s10434-009-0470-0. Epub 2009 May 1. Erratum in: Ann Surg Oncol. 2009 Sep;16(9):2668. Neylon, Ellen [added]; MacGregor-Cortelli, Barbara [added]; Patterson, Molly [added].

PMID:
19408055
9.

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.

Marneros AG, Grossman ME, Silvers DN, Husain S, Nuovo GJ, MacGregor-Cortelli B, Neylon E, Patterson M, O'Connor OA, Zain JM.

Blood. 2009 Jun 18;113(25):6338-41. doi: 10.1182/blood-2009-03-210989. Epub 2009 Apr 23.

10.

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.

O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J.

Br J Haematol. 2009 Apr;145(1):34-9. doi: 10.1111/j.1365-2141.2008.07466.x. Epub 2009 Feb 6.

PMID:
19220284
11.

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.

O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, Macgregor-Cortelli B, Neylon E, Sarasohn D, Dumetrescu O, Mould DR, Fleischer M, Zelenetz AD, Sirotnak F, Horwitz S.

Br J Haematol. 2007 Nov;139(3):425-8.

PMID:
17910632
12.

Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association.

Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association.

Med J Aust. 2007 May 7;186(9):461-5.

PMID:
17484708
13.

Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, Esseltine D, Boral A, Schenkein D, Busam K, Teruya-Feldstein J, Sachs D, O'Connor OA.

Br J Haematol. 2006 Aug;134(4):391-8.

PMID:
16882131

Supplemental Content

Loading ...
Support Center